Introduction {#s1}
============

Hepatitis C virus (HCV) infects an estimated 71 million people worldwide ([@bib52]) and can lead to severe liver disease in chronically infected patients. The virus is highly variable and has been classified into seven distinct genotypes, and further divided into 67 subtypes, based on nucleotide sequence diversity ([@bib42]). The factors that have driven the evolutionary path of HCV are multifactorial but undoubtedly are also shaped by host genetics. Because of its major health burden, determining how both host and viral genetics contribute to the outcomes of infection is critical for a better understanding of HCV-mediated pathogenesis ([@bib37]) and the immune response to viral infection.

Using a systematic genome-to-genome approach in a cohort of chronically infected patients, we recently reported associations between an intronic single nucleotide polymorphism (SNP) rs12979860 in the interferon lambda 4 (*IFNL4*) gene (CC vs. non-CC) and 11 amino acid polymorphisms on the HCV polyprotein ([@bib5]) at a 5% false discovery rate (FDR) ([@bib13]). This observation was unexpected since *IFNL4* is a member of the type III interferon (IFN-λ) family that act as cytokines as part of the innate immune system and therefore lack apparent epitope specificity ([@bib14]). These associations between polymorphisms on the HCV polyprotein and host *IFNL4* SNP rs12979860 genotypes are further intriguing given that variants within the *IFNL4* locus (including SNP rs12979860) contribute to HCV clinical and biological outcomes, including spontaneous virus clearance, response to IFN-based treatment, viral load and liver disease progression ([@bib7]; [@bib26]; [@bib34]; [@bib35]; [@bib39]; [@bib46]; [@bib47]; [@bib49]). It is possible that the associations between the outcomes of HCV infection and the *IFNL4* locus are directly linked to its impact on the viral genome and the encoded polyprotein.

The intronic *IFNL4* SNP rs12979860 is in high linkage disequilibrium with other SNPs that may be more biologically relevant, including the exonic dinucleotide variant rs368234815 (r^2^ = 0.975 CEU population, 1000 Genomes dataset) in *IFNL4*. This variant \[ΔG \> TT\] causes a frameshift, abrogating production of functional IFN-λ4 protein ([@bib38]). Moreover, several amino acid substitutions within IFN-λ4 have been shown to alter its antiviral activity ([@bib10]; [@bib48]). In particular, a common amino acid substitution (coded by the SNP rs117648444 \[G \> A\]) in the IFN-λ4 protein, which changes a proline residue at position 70 (P70) to a serine residue (S70), reduces its antiviral activity in vitro ([@bib48]). Thus, the combination of alleles at rs368234815 and rs117648444 creates four potential haplotypes, two that do not produce IFN-λ4 protein (TT/G or TT/A; IFN-λ4-Null) and two that result in production of two IFN-λ4 protein variants (ΔG/G; IFN-λ4-P70 and ΔG/A; IFN-λ4-S70). Patients harbouring the impaired IFN-λ4-S70 variant display lower hepatic interferon-stimulated gene (ISG) expression levels, which is associated with increased viral clearance following acute infection and a better response to IFN-based therapy, compared to patients carrying the more active IFN-λ4-P70 variant ([@bib23]).

In this study, we report a large number of associations between HCV-encoded amino acids across the viral polyprotein and host *IFNL4* SNP rs12979860, with 42 significant associations at a 5% FDR, increasing to 76 viral sites at a 10% FDR. The associations are observed in both structural and non-structural viral proteins and no enrichment of association signals is observed in any of the viral proteins or HLA restricted epitope regions. We also find an association with viral nucleotide content and certain dinucleotide frequencies, such as UpA (uracil base followed by adenine base). Finally, we demonstrate that *IFNL4* haplotypes coding for IFN-λ4-S70 and IFN-λ4-P70 variants differ in terms of their impact on viral load and viral amino acid polymorphisms, in agreement with the reduced antiviral activity of IFN-λ4-S70. Together these observations suggest that IFN-λ4 is a driver of HCV sequence diversity and modulator of viral load.

Results {#s2}
=======

Host and virus genetic structures {#s2-1}
---------------------------------

To ensure that host and virus population structures had a minimal impact on our results, we used paired genome-wide human and viral genetic data in a homogenous group of 485 patients with self reported white ancestry, infected with HCV genotype 3a from two cohorts \[BOSON ([@bib24]) and Expanded Access Program (EAP) ([@bib25]) cohorts, N~BOSON~ = 411, N~EAP~ = 74, see [Supplementary file 1](#supp1){ref-type="supplementary-material"} and Materials and methods for a description of the cohorts\]. To control for both human and virus population structures, we performed principal component analysis (PCA) on each of the host and viral genetic data (Materials and methods). The host PCA defined a largely homogenous group corresponding to self-reported white ancestry ([Figure 1---figure supplement 1a](#fig1s1){ref-type="fig"}). The first and second viral principal components (PCs) explained around 3% and 2% of variance in HCV nucleotide diversity respectively ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}), indicating a homogenous group of isolates as observed by the long terminal and short internal branches of the phylogenetic tree ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). The viral sequences from the two cohorts were non-randomly distributed on the tree as one clade was underrepresented in the EAP cohort sequences; this clade corresponded to isolates in the BOSON cohort from outside the United Kingdom (treeBreaker Bayes factor = 249, see Materials and methods for an explanation on how to interpret Bayes factor and [Figure 1---figure supplement 3a](#fig1s3){ref-type="fig"}). This observation was not reflected in host *IFNL4* SNP rs12979860 genotypes, which were randomly distributed on the viral phylogenetic tree (treeBreaker Bayes factor = 1.1, [Figure 1---figure supplement 3b](#fig1s3){ref-type="fig"}). However, we did observe associations between the host *IFNL4* SNP rs12979860 and the fifth and seventh viral PCs (p=1.3×10^−15^ and 7.2 × 10^−9^, respectively), which were not directed by host-virus population co-structuring, suggesting that the *IFNL4* locus drives HCV nucleotide diversity ([Figure 1---figure supplement 2b--d](#fig1s2){ref-type="fig"} and Appendix 1).

The *IFNL4* locus affects virus-encoded amino acids at specific sites across the HCV polyprotein {#s2-2}
------------------------------------------------------------------------------------------------

A major advantage of determining entire HCV genomic sequence data is the possibility to perform footprinting analysis at a genome-wide scale. The nucleotide and amino acid frequencies at polymorphic viral sites in the two cohorts were similar and no systematic differences were observed ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). We used logistic regression to test for association between *IFNL4* SNP rs12979860 genotypes (CC vs. non-CC) and virus-encoded amino acids, including the first two viral PCs and the first three host PCs as covariates to account for host-virus population co-structuring. Presence or absence of each viral amino acid was used as the response variable; 977 tests were performed at 471 viral sites. To test for possible confounders we separately added each of the cirrhosis status of patients, cohorts (BOSON vs. EAP), gender and age to the model as covariates. These covariates were not associated with any specific amino acids at a 10% FDR (data not shown).

At a 5% FDR, 42 of the viral sites tested were associated with *IFNL4* SNP rs12979860, increasing to 76 sites at a 10% FDR ([Figure 1](#fig1){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). This represented 1.4% at a 5% FDR and 2.5% at a 10% FDR of all the viral amino acids in the HCV genotype 3a polyprotein (N = 3021), reflecting a large impact of the host *IFNL4* locus on the amino acids encoded at variable sites on the viral polyprotein. The most associated viral site was at position 2570 in the NS5B protein (p=1.32×10^−8^, log(OR)=1.19), as previously reported ([@bib5]). Notably, 26 of the 76 sites (34%) associated with the *IFNL4* SNP rs12979860 at a 10% FDR lie within the HCV E2 glycoprotein (Appendix 1 and [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). However, we did not observe significantly enhanced enrichment or depletion for association signals in any specific viral protein, or in previously reported HLA restricted epitope regions in HCV genotype 3a ([@bib50]) ([Supplementary file 3](#supp3){ref-type="supplementary-material"} and Materials and methods).

![HCV genome-wide association study with *IFNL4* SNP rs12979860 genotypes (CC vs. non-CC).\
(**a**) Manhattan plot. The dashed line indicates 5% FDR. At this level 42 sites on the virus polyprotein are significantly associated with *IFNL4* SNP. (**b**) Schematic of the HCV polyprotein.](elife-42463-fig1){#fig1}

To ensure that host-virus population co-structuring or some other systematic bias was not confounding our results, we performed the same tests against the HCV amino acids for 500 host SNPs from across the human genome with a minor allele frequency (MAF) similar to *IFNL4* SNP rs12979860 MAF, further referred to as 'the 500 frequency-matched SNPs'. In effect we performed 500 viral GWASs, one for each of the 500 frequency-matched SNPs. Using a 5% FDR (calculated independently for each of the 500 viral GWASs), we observed no significant associations for 491 of the host SNPs tested against the HCV polyprotein. The remaining nine host SNPs were associated with one HCV amino acid each ([Supplementary file 4](#supp4){ref-type="supplementary-material"}). However, these associations are likely to be false positives as multiple testing corrections were performed for each viral GWAS independently. Additionally, the distribution of P-values for the association tests between HCV amino acids and the 500 frequency-matched SNPs followed the null distribution of no associations ([Figure 1---figure supplement 6a](#fig1s6){ref-type="fig"}), confirming that there was no systematic bias in our analysis. By comparison, the distribution of the P-values for the association tests between HCV amino acids and *IFNL4* SNP rs12979860 deviated from the null distribution of no associations. This observation and the large number of HCV amino acids significantly associated with *IFNL4* SNP rs12979860 genotypes highlighted that the broad impact of the *IFNL4* locus on HCV-encoded amino acids was authentic and not driven by host-virus population co-structuring.

We then explored nucleotide sequences at the codon level to distinguish the impact of the *IFNL4* SNP rs12979860 on viral nucleotides as distinct from its effect on viral amino acids. We tested for associations between host *IFNL4* SNP rs12979860 and HCV codon changes from the most common codon to synonymous and non-synonymous codons (Materials and methods). For each HCV codon site with at least 20 synonymous and 20 non-synonymous codons (N = 348), we performed a logistic regression including the first two viral PCs and the first three host PCs to test for association between *IFNL4* SNP rs12979860 (and the 500 frequency-matched SNPs as in the previous section) and changes from the most common codon to synonymous and non-synonymous codons (Materials and methods). We observed that non-synonymous changes at 16 viral codons were significantly associated with *IFNL4* SNP rs12979860 at a 5% FDR, increasing to 35 viral codons at a 10% FDR ([Supplementary file 5](#supp5){ref-type="supplementary-material"}). As expected the 500 frequency-matched SNPs did not show the same level of associations with HCV non-synonymous codon changes ([Figure 1---figure supplement 6b](#fig1s6){ref-type="fig"}). We also observed that synonymous changes at two viral codons were significantly associated with *IFNL4* SNP rs12979860 at a 5% FDR, increasing to four viral codons at a 10% FDR ([Supplementary file 6](#supp6){ref-type="supplementary-material"} and [Figure 1---figure supplement 6c](#fig1s6){ref-type="fig"}). This indicates that the effect of the *IFNL4* locus on virus sequence diversity is mostly at the amino acid level, although a small impact on nucleotide substitutions cannot be excluded.

We hypothesised that the observed impact of *IFNL4* SNP rs12979860 on viral nucleotide sequences might be induced through dinucleotide sensing mechanisms. Most viruses suppress genomic CpG and UpA dinucleotide frequencies, supposedly to mimic host mRNA composition and avoid the immune response ([@bib43]). To explore this possibility, we tested the association between the dinucleotide frequencies in each viral sequence and the host *IFNL4* SNP rs12979860 (Materials and methods). The viral UpA dinucleotide frequency (estimated as the ratio of observed to expected frequencies) was significantly lower in the host individuals with *IFNL4* SNP rs12979860 non-CC group compared to the CC group (p=1.5×10^−6^, [Figure 1---figure supplement 7](#fig1s7){ref-type="fig"}). By contrast, the viral UpG dinucleotide frequency was significantly higher in the *IFNL4* SNP rs12979860 non-CC group compared to the CC group (p=1.5×10^−5^). The viral CpC and CpA dinucleotide frequencies were also significantly different between the individuals with *IFNL4* SNP rs12979860 CC and non-CC genotypes (p=3.3×10^−4^ and p=3.3×10^−4^, respectively). Similar results were observed by analysing the cohorts independently (Appendix 1 and [Figure 1---figure supplement 8](#fig1s8){ref-type="fig"}).

IFN-λ4 protein impacts on viral amino acid variation and viral load {#s2-3}
-------------------------------------------------------------------

We then investigated the impact of the different haplotypes of *IFNL4* on HCV amino acid diversity and viral load to refine its possible role. After imputing and phasing *IFNL4* rs368234815 and rs117648444 (Materials and methods), we observed three haplotypes: TT/G (IFN-λ4-Null); ΔG/G (IFN-λ4-P70) and ΔG/A (IFN-λ4-S70). HCV-infected patients were classified into three groups according to their predicted ability to produce IFN-λ4 protein: (i) no IFN-λ4 (two allelic copies of IFN-λ4-Null, N~BOSON~ = 145, N~EAP~ = 41), (ii) IFN-λ4--S70 (two copies of IFN-λ4-S70 or one copy of IFN-λ4-S70 and one copy of IFN-λ4-Null, N~BOSON~ = 48, N~EAP~ = 7), and (iii) IFN-λ4-P70 (at least one copy of IFN-λ4-P70, N~BOSON~ = 218, N~EAP~ = 26) ([Supplementary file 7](#supp7){ref-type="supplementary-material"}).

Since IFN-λ4-S70 can be distinguished phenotypically from IFN-λ4-P70 both in vivo and in vitro, we examined whether the *IFNL4* haplotypes had distinct effects on viral amino acid polymorphisms and viral load. We estimated the effect size of IFN-λ4-S70 and IFN-λ4-P70 relative to the IFN-λ4-Null haplotype on the presence and absence of the 76 amino acids associated with *IFNL4* SNP rs12979860 genotypes at a 10% FDR. We found that the estimated effect sizes of IFN-λ4-S70 were consistently smaller than those for IFN-λ4-P70 ([Figure 2](#fig2){ref-type="fig"}). Under the null hypothesis that there is no difference in the effect sizes of IFN-λ4-P70 and IFN-λ4-S70 variants on viral amino acid polymorphisms, we would expect the slope of the linear regression line ([Figure 2](#fig2){ref-type="fig"}) to have a value of one. However, the estimated slope of the best-fit line was significantly different from one (slope = 0.77, p=9.6×10^−7^, [Figure 2](#fig2){ref-type="fig"}). Additionally, we used bootstrapping to account for the uncertainty associated with the estimated effect sizes of IFN-λ4-P70 and IFN-λ4-S70 variants on HCV amino acid polymorphisms (Materials and methods). When estimating the slope of the line, we observed that the bootstrap 95% confidence interval \[0.69, 0.99\] for the slope of the line did not include one. Thus, we concluded that the impact of the host IFN-λ4-S70 variant on HCV-encoded amino acids was significantly smaller than the IFN-λ4-P70 variant.

![Comparison of the effect sizes (log(OR)) of host IFN-λ4 variants (IFN-λ4-S70 and IFN-λ4-P70 relative to IFN-λ4-Null) on HCV-encoded amino acids.\
The circles show the log(OR) estimates and the grey lines indicate the 95% confidence intervals. The dashed line is the y = x line which has a slope of one. The solid black line shows the linear regression line, which has a slope of 0.77 that is significantly different from one (y = x line, p=9.6×10^−7^).](elife-42463-fig2){#fig2}

We then investigated the effects of IFN-λ4 haplotypes on viral load. For this analysis, the EAP cohort was excluded as these patients had advanced liver disease with consistently lower viral loads relative to the BOSON cohort ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We observed no difference in mean viral load between patients carrying IFN-λ4-S70 and IFN-λ4-Null haplotypes (p=0.61). However, the viral load in patients carrying IFN-λ4-P70 was significantly lower than in the other two groups (*P~IFN-λ4-S70~* = 1.6×10^−4^ and *P~IFN-λ4-Null~* = 3.9×10^−10^), with IFN-λ4-P70 conferring an approximately 2.3-fold decrease in viral load compared to IFN-λ4-S70 (mean for IFN-λ4-P70 = 2,905,333, IFN-λ4-S70 = 6,703,875 and IFN-λ4-Null = 6,256,523 IU/ml, [Figure 3a](#fig3){ref-type="fig"}).

![Bayesian model comparison of effect sizes of IFNL-λ4 variants on viral load in the BOSON cohort (N = 411).\
(**a**) Pretreatment viral load stratified by the host IFN-λ4 variants. The black dots and lines indicate the mean and 95% confidence interval (CI) for each group. (**b**) The posterior probability of the five tested models from (**a**) stacked on top of each other (from model 1 to model 5; posterior probabilities of models 1, 2 and 5 are too small to be labelled on this plot). Models where the posterior probability is higher or lower than the prior probability are coloured as dark grey and light grey respectively. Only model 3 (as indicated) has a posterior probability bigger than its prior probability and it assumes that the mean viral load is identical in IFN-λ4-Null and IFN-λ4-S70 groups and different from the mean viral load of IFN-λ4-P70 group. (**c**) Viral load stratified by the host IFNL-λ4 variants and the presence and absence of serine at the viral amino acid site 2414. The black dots and lines indicate the mean and 95% CI for each group. (**d**) The posterior probability of the 58 tested models from (**c**) stacked on top of each other (from model 1 to model 58; only models where the posterior probability is higher than the prior probability are labelled on this plot). Models where the posterior probability is higher or lower than the prior probability are coloured as dark grey and light grey respectively. Model 5 has the highest posterior probability and it assumes that the mean viral load is only different in 'IFN-λ4-P70 + 2414 serine' group and identical in other groups.](elife-42463-fig3){#fig3}

We used a Bayesian approach to investigate the relationship between the effect sizes of the three IFN-λ4 haplotypes on viral load ([Figure 3b](#fig3){ref-type="fig"}). In essence, this method weighs up the evidence that the genetic effects of the IFN-λ4-Null, IFN-λ4-S70 and IFN-λ4-P70 haplotypes are the same or not relative to each other (Materials and methods). We tested five models; the effects of the three haplotypes are identical (model 1), the effects of IFN-λ4-P70 and IFN-λ4-Null are identical and different from the effect of IFN-λ4-S70 (model 2), the effects of IFN-λ4-S70 and IFN-λ4-Null are identical and different from the effect of IFN-λ4-P70 (model 3), all three haplotypes have different effect sizes (model 4) and the effects of IFN-λ4-P70 and IFN-λ4-S70 are the same but different from the effect of IFN-λ4-Null haplotype (model 5). Equal prior probabilities were used for all models. Model 3 had the highest posterior probability of 0.82 ([Figure 3b](#fig3){ref-type="fig"}).

We had previously reported an association between *IFNL4* SNP rs12979860 genotypes, the HCV-encoded amino acids at position 2414 in the polyprotein and viral load ([@bib5]). In the present study, we further stratified the analysis by *IFNL4* haplotypes. The viral serine (S) residue at site 2414 (S2414) was significantly enriched in patients coding for the IFN-λ4-P70 variant compared to IFN-λ4-S70 (p=3.39×10^−03^) and IFN-λ4-Null (p=5.94×10^−09^) coding patients. S2414 was present in 86% (211/244) of IFN-λ4-P70 carrying patients, 69% (38/55) of IFN-λ4-S70 carrying patients and 62% (114/185) of IFN-λ4-Null carrying patients. In HCV-infected patients with a serine residue at position 2414, we observed no significant difference in mean viral load between IFN-λ4-Null and IFN-λ4-S70 carriers (p=0.31, [Figure 3c](#fig3){ref-type="fig"}), but both groups had a significantly higher viral load than IFN-λ4-P70 carriers (p~IFN-λ4-Null~=2.7x10^−9^; p~IFN-λ4-S70~=1.6x10^−10^). However, no such association (p=0.49) was found in HCV-infected patients with a non-serine residue at this site ([Figure 3c](#fig3){ref-type="fig"}). We performed a Bayesian analysis that compared 58 possible models against each other (from all effect sizes being the same to all being different from each other). The model where only the 'IFN-λ4-P70 + S2414' group had an effect size different from the other groups (model 5) had the highest posterior probability of 0.33 ([Figure 3d](#fig3){ref-type="fig"} and Appendix1). Taken together, the combination of IFN-λ4-P70 and S2414 conferred a 2.6-fold decrease in viral load compared to IFN-λ4-S70 and S2414 (mean viral load for IFN-λ4-P70 and S2414 = 2,376,747 IU/ml, and mean viral load IFN-λ4-S70 and S2414 = 6,093,167 IU/ml).

Discussion {#s3}
==========

Here, we show that genetic variants in the human *IFNL4* locus drive widespread sequence changes across the entire HCV polyprotein - much larger than we previously reported ([@bib5]). We did not observe statistically significant enrichment of association signals in any specific HCV protein nor in HLA restricted epitope regions. This indicates that the host *IFNL4* locus, and hence the innate immune response, can influence the amino acid residues that are encoded at specific sites on the HCV polyprotein. The mechanism of action of IFN-λ4 in determining such selectivity is not known. We also report an association of the *IFNL4* locus with synonymous codon variants, suggesting that this locus might also affect the HCV genome at the nucleotide sequence level. Finally, we report that the *IFNL4* haplotype coding for the IFN-λ4-S70 variant has a smaller impact on viral load and viral amino acid variation at associated sites compared to the haplotype coding for the more active IFN-λ4-P70 variant. This indicates that the *IFNL4* gene not only mediates HCV amino acid variation but also modulates viral load in patients. Hence, our findings extend the association between genetic variation in the *IFNL4* locus and outcome of HCV infection as well as hepatic disease ([@bib7]; [@bib26]; [@bib34]; [@bib35]; [@bib39]; [@bib46]; [@bib47]; [@bib49]; [@bib23]).

We selected patients chronically infected with HCV genotype 3a and of self-reported white ancestry to limit the impact of human and viral population co-structuring in our analyses. We observed that 2.5% of HCV-encoded amino acids across the polyprotein were significantly associated with host *IFNL4* SNP at a 10% FDR. No such association was observed for 500 host SNPs chosen from across the human genome with a MAF similar to that for *IFNL4* SNP rs12979860. This indicated that the observed impact of *IFNL4* SNP rs12979860 on the viral sequences was not due to population structure or other systematic bias. Compared to our previous report ([@bib5]), the number of sites associated with *IFNL4* genotype increased from 11 to 42 at a 5% FDR. One of the 11 previously reported associations was not reproduced (position 2576) as it was not tested in this study, due to more stringent frequency filtering (an amino acid had to be present in at least 20 samples to be tested). Thus, we have identified a further 32 associated sites at a 5% FDR compared to our previous report. There are two key factors that have contributed to this increased number of associated sites. Firstly, only HCV genotype 3a sequences found in those of white ancestry have been included in the analysis; our previous report included HCV genotype 2 and other genotype 3 subtypes from a broader ethnic mix. Secondly, we have used logistic regression and accounted for population structure by including viral and host genetic PCs as covariates in the analysis. This approach has recently been shown to be more powerful to detect associations in genome-to-genome analysis ([@bib33]). Thus, focusing on a homogenous population (white ethnicity infected with genotype 3a) and using logistic regression has increased the power of our study to detect many more associations between the *IFNL4* locus and amino acid variation in the HCV polyprotein.

To distinguish the effect of *IFNL4* SNP rs12979860 on viral amino acid variation from nucleotide sequence variability, we investigated the association of the host *IFNL4* SNP rs12979860 with synonymous and non-synonymous codon changes in the HCV genome. *IFNL4* SNP rs12979860 genotypes were associated with 35 non-synonymous codon changes at a 10% FDR, but we also observed four significant associations with synonymous codon changes. This indicated that in addition to a widespread impact at the amino acid level, the *IFNL4* locus may also independently drive nucleotide diversity but to a lesser extent.

To further explore the impact of the *IFNL4* variants on HCV genomic sequences, we investigated viral dinucleotide frequencies. The HCV UpA dinucleotide frequency was significantly associated with the *IFNL4* SNP rs12979860 genotypes; interestingly, ribonuclease L (RNase-L), an ISG that cleaves viral RNA to control viral infections in animals ([@bib19]), targets both UpA and UpU dinucleotides ([@bib54]). Moreover, HCV genotype 1, which is relatively resistant to IFN-based therapy, has a lower frequency of UpA and UpU dinucleotides than the more IFN-sensitive HCV genotypes 2 and 3 ([@bib16]; [@bib30]). Indeed, the UpA dinucleotide is targeted by RNA-degrading enzymes and its presence in a RNA sequence accelerates its degradation in the cytoplasm ([@bib43]). It is possible that the more stringent immune environment of non-CC patients (with higher hepatic expression of ISGs) selects virus with a lower UpA frequency. However, we note that the *IFNL4* SNP rs12979860 non-CC patients have a modest reduction (0.9%) in their viral UpA frequencies relative to the CC patients and that this reduction could be mediated by the widespread amino acid changes associated with the *IFNL4* SNP rs12979860.

Previous studies have shown that IFN-λ4-P70 and IFN-λ4-S70 variants of IFN-λ4 protein have distinct phenotypes, both in vivo and in vitro. We hypothesized that if IFN-λ4 contributes to changes in the viral polyprotein, then the IFN-λ4-P70 and IFN-λ4-S70 variants should have different effect sizes on HCV-encoded amino acids and viral load. By imputing and phasing *IFNL4* SNPs in our cohort, we inferred the haplotypes consisting of the *IFNL4* rs368234815 (ΔG/TT) and rs117648444 (G/A) variants. Using these data, we observed that the haplotype coding for the IFN-λ4-S70 variant had a smaller effect on viral amino acid variability compared to the haplotype coding for the IFN-λ4-P70 variant. This observation agrees with previous independent studies showing the reduced antiviral activity for IFN-λ4-S70 in vitro ([@bib10]; [@bib48]). Moreover, the mean viral load in IFN-λ4-Null carrying patients was similar to those carrying the IFN-λ4-S70 variant; by contrast, those carrying an IFN-λ4-P70 variant had a reduced viral load, which correlates with its higher antiviral activity. Taken together, these observations reinforce the hypothesis that *IFNL4* is a functional gene with a major role in HCV infection. We conclude that production of IFN-λ4 protein drives an altered immune response that mediates reduced viral load with a broad impact on viral amino acid diversity.

In this study, we demonstrated by using paired host-HCV genomic data that host *IFNL4* gene, a cytokine that is part of the innate immune response and not expected to target specific viral residues, can mediate selection of amino acids at specific sites on the HCV polyprotein. We report that 1.4% (42/3021) of the HCV amino acids across the viral polyprotein are associated with host *IFNL4* SNP rs12979860 at a 5% FDR and that the impact on amino acid variation is spread across all viral proteins. In comparison, we previously reported that 0.7% of the HCV amino acids were associated with *HLA* class I and II alleles ([@bib5]) at a 5% FDR. The only other major driver of HCV amino acid variation is the host B cell response, which is largely restricted to modifying amino acids in the envelope glycoproteins, in particular E2 ([@bib9]). Thus, although both arms of the adaptive immune system direct amino acid selection through pressure on epitopes recognised by T and B cell responses to infection, our results show that the innate immune response also has the capacity to drive particular polymorphisms in HCV-encoded proteins and that its impact is comparable to that of the T cell response (as indicated by HCV amino acid variants associated with HLA alleles).

Given that we did not observe any significant enhancement or depletion of association signals in a specific viral protein or in HLA-restricted epitopes, IFN-λ4 may exert its impact through a previously unknown mechanism or at more than one stage of the virus life cycle. We anticipate that this would result from distinct host responses in those who carry genetic variants that lead to IFN-λ4 synthesis as compared to individuals who carry the pseudogenized form of the gene. In common with other IFNs, IFN-λ4 induces a large number of ISGs, many of which are largely unstudied or poorly characterised. Within such an environment, it is possible that subtle selection of certain amino acids along the polyprotein will provide an advantage for viral entry, RNA replication, virion assembly and release.

Although there was no significant enrichment of associations comparing the structural with the non-structural proteins, the E2 glycoprotein contained the highest proportion of sites affected by *IFNL4* SNP rs12979860. From mapping these sites onto previously known functional domains on E2, we found that many residues were located either in hypervariable region 1 (HVR1) or on the surface of the protein. Indeed, some sites coincided with epitopes that are targets for the antibody response or have a role in virus entry (Appendix 1 and [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). Since the host response to HCV genotype 3a infection induces pathways including those affecting B cell development ([@bib40]), we do not exclude the possibility that *IFNL4* SNP rs12979860 genotype either influences B cell response to infection or the process of virus binding and entry. Indeed, a recent report has demonstrated the emergence of variants in E2 during establishment of chronic infection that give enhanced resistance to interferon-induced transmembrane (IFITM) proteins ([@bib53]). One of the E2 residues that encoded a different amino acid as chronicity developed was at position 500, which is an *IFNL4*-associated site ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Given that IFITM proteins potently inhibit virus entry, it is possible that differences in IFITM induction between those who do and do not produce IFN-λ4 may account for some of the footprint observed in the E2 protein sequence. Moreover, IFITM proteins cooperate with anti-HCV neutralising antibodies to enhance restriction of virus entry. Therefore, there may be interaction between genes differentially regulated between IFN-λ4 producers and non-producers and components of the adaptive immune system, which together influence the amino acids encoded at certain *IFNL4*-associated sites ([@bib53]).

To reduce any confounding effects due to population stratification, we limited our analysis to a homogenous population of self-reported white origin infected with HCV genotype 3. Thus, our observations cannot directly be extended to other human populations or other HCV genotypes. This study provides a foundation for future analysis on whether *IFNL4* genetic variation also drives diversity in other HCV genotypes and subtypes across other ethnic populations (also see 'Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes' by Chaturvedi *et al.* in this issue). Additionally, our observations were performed with in vivo data; further functional studies using appropriate in vitro model systems are needed to understand how the *IFNL4* locus drives HCV amino acid variation and modulates viral load. Such studies may also help to inform the basis for diversity and evolution of HCV in the presence or absence of *IFNL4*.

There are now multiple studies suggesting that the *IFNL3-IFNL4* locus could be a key player in the defense against viruses other than HCV. In HIV-infected patients, the rs368234815 variant has been associated with long-term non-progressor HIV-1 controllers ([@bib20]). In influenza virus infection, *IFNL4* SNP rs8099917 was associated with increased sero-conversion after influenza vaccination ([@bib21]). *IFNL4* variants have also been associated with bronchiolitis ([@bib41]), cytomegalovirus ([@bib22]) and Andes virus ([@bib4]) infections. These observations suggest that *IFNL4* possibly plays a role in many viral infections and immune related diseases in the liver and other organs. Investigating how IFN-λ4 (a cytokine without epitope specificity) drives amino acid selectivity in the HCV polyprotein would add a new dimension to how the human innate immune system interacts with viruses and controls infectious diseases.

Materials and methods {#s4}
=====================

Patient cohorts {#s4-1}
---------------

For this study, we used patient data from the BOSON and EAP cohorts that have been described elsewhere ([@bib24]; [@bib25]). All patients provided written informed consent before undertaking any study-related procedures. The BOSON study protocol was approved by each institution's review board or ethics committee before study initiation. The study was conducted in accordance with the International Conference on Harmonisation Good Clinical Practice Guidelines and the Declaration of Helsinki (clinical trial registration number: NCT01962441). The EAP study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee. The EAP patients were enrolled by consent into the HCV Research UK registry. Ethics approval for HCV Research UK was given by NRES Committee East Midlands - Derby 1 (Research Ethics Committee reference 11/EM/0314).

Patients from the BOSON cohort were recruited in five different countries (Australia, Canada, New Zealand, United Kingdom and United States). Patients from the EAP cohort were recruited exclusively in the United Kingdom.

To limit the potential impact of population structure, we restricted the analysis to patients of self-reported white ancestry infected with HCV genotype 3a for which we had obtained both host genome-wide SNP data and full-length HCV genome sequences. In total we included 485 patients in the study, 411 from the BOSON cohort and 74 from the EAP cohort.

The majority of the patients from the BOSON cohort have no or mild liver disease (compensated liver cirrhosis). The EAP cohort on the other hand consists of HCV-infected patients with advanced liver disease, the majority of whom had decompensated cirrhosis.

Host genotyping and imputation {#s4-2}
------------------------------

Informed consent for genetic analysis was obtained from all patients. Genomic DNA was extracted from buffy coat using Maxwell RSC Buffy Coat DNA Kit (Promega) as per the manufacturer\'s protocol and quantified using Qubit (Thermofisher). DNA samples from patients were genotyped using the Affymetrix UK Biobank array, as described elsewhere ([@bib5]). Phasing and imputation was performed using SHAPEIT2 ([@bib18])[@bib15] and IMPUTE2 ([@bib27]) version 2.3.1 using default settings and the 1000 Genomes Phase III dataset as a reference population ([@bib8]). Imputation quality was high for both rs117648444 and rs368234815 variants (information 0.974 and 0.994 respectively and certainty 0.995 and 0.997 respectively). Patients from the EAP cohort from whom enough DNA was available (62/74) were also independently genotyped for both rs117648444 and rs368234815 variants. Genotyping of *IFNL4* rs368234815 and rs117648444 was performed on DNA using the TaqMan SNP genotyping assay and sequences described previously ([@bib38]) with Type‐it Fast SNP Probe PCR Master Mix (Qiagen). The concordance between genotyped and imputed genotypes was 100% for both variants.

Virus sequencing {#s4-3}
----------------

The generation and assembly of viral sequences from HCV-infected clinical samples for the BOSON and EAP cohorts have been described previously ([@bib5]; [@bib44]).

Statistical analysis {#s4-4}
--------------------

### Human and viral population structure {#s4-4-1}

For the viral data, principal component analysis (PCA) was performed on the nucleotide data as follows. The presence and absence of each viral nucleotide at all variable sites in the alignment was coded as a binary variable such that a bi-allelic site on the viral genome was converted into two binary variables (one for each nucleotide), a tri-allelic site into three binary variables and a quad-allelic site into four binary variables. R (version 3.4.3, <https://www.r-project.org>) was then used to perform the PCA using the prcomp function with default settings. PCA was performed using flashpca ([@bib1]) for human genotype data.

Whole-genome viral consensus sequences for each patient were aligned using MAFFT ([@bib29]) with default settings. This alignment was used to create a maximum-likelihood tree using RAxML ([@bib45]), assuming a general time-reversible model of nucleotide substitution under the gamma model of rate heterogeneity. The resulting tree was rooted at midpoint.

We used treeBreaker software ([@bib6]) (<https://github.com/ansariazim/treeBreaker>) to measure the association between the virus phylogenetic tree and the host *IFNL4* SNP (CC vs. non-CC) and with the cohort from which the viral sequence was obtained (BOSON vs. EAP). This software uses a Bayesian model to infer whether the phenotype of interest is randomly distributed on the tips of the tree and to estimate which clades, if any, have a distinct distribution of the phenotype of interest from the rest of the tree. This software also performs Bayesian model comparison. It provides a Bayes factor for the alternative model (there is at least one or more branches with distinct distribution of the phenotype of interest) to the null model (there are no branches with distinct phenotype distribution on the tree). Bayes factor is a summary of the evidence provided by the data in favour of one model compared to another. In other words, the higher the Bayes factor, the more support there is for one model against another. Assuming that we are testing an alternative model against a null model, it has been suggested that the Bayes factor can be divided into four categories ([@bib28]). Bayes factor: 1 to 3.2, very little evidence against the null model. Bayes factor: 3.2 to 10, substantial evidence against null model and in favour of the alternative model. Bayes factor: 10 to 100, strong evidence against null model and in favour of the alternative model. Bayes factor:\>100, decisive evidence against null model and in favour of the alternative model.

### Association tests {#s4-4-2}

The univariate association between the *IFNL4* SNP rs12979860 (CC vs. non-CC) and the viral PCs was tested using logistic regression in R. We used the qvalue function from the qvalue package in R to perform the FDR analysis.

To choose 500 SNPs across the human genome with minor allele frequency (MAF) similar to the *IFNL4* SNP rs12979860 MAF, we used Fisher's exact test to compare all SNPs against the *IFNL4* SNP rs12979860 (2 × 3 contingency table where the columns indicate the number of 0, 1 and 2 copies of the minor allele and the rows indicate the *IFNL4* SNP and the target SNP counts) and chose the 500 SNPs with the largest P-values (least significance). SNPs in the *IFNL3-IFNL4* region were not included.

To test for association between the virus amino acids and the host SNPs we used logistic regression in R including as covariates the first three host and the first two viral PCs. We investigated presence and absence of each amino acid at all variable sites, given that the amino acid was present in at least 20 HCV sequences in our dataset. The presence and absence of the viral amino acid was used as the response variable and the host SNP coded as 0 (homozygous for major alleles) and 1 (all other genotypes) as the explanatory variable (the same coding as the *IFNL4* SNP rs12979860 CC vs. non-CC).

To test for enrichment or depletion of the association signals in a viral protein or the epitope regions, we used Fisher's exact test. Each tested site is either within the target region or not and it is either classified as significant or not. The resulting 2 × 2 contingency table was tested using fisher.test function in R.

### Codon level analysis {#s4-4-3}

To separate the impact of the *IFNL4* SNP rs12979860 on amino acids from nucleotides we investigated the nucleotide sequences at the codon level. At each codon site (where the most common codon had at least 20 synonymous and 20 non-synonymous codons) we used logistic regression to test for association between *IFNL4* SNP rs12979860 (CC vs. non-CC) and the changes from the most common codon to synonymous and non-synonymous codons. The *IFNL4* SNP rs12979860 was denoted as the response variable and the codons were used as a categorical explanatory variable with three levels. The effect sizes (log(OR)) and P-values were estimated for the synonymous and non-synonymous codons relative to the most common codon. We included the first two viral PCs and the first three host PCs as covariates in this analysis.

### Di-nucleotides analysis {#s4-4-4}

To estimate the viral dinucleotide frequencies, the observed proportion of each dinucleotide was normalised by its expected proportion (assuming the nucleotides are independent the expected proportion can be calculated by multiplying the observed proportions for the relevant nucleotides). To test for association with *IFNL4* SNP rs12979860 genotype we used a linear regression where the normalised dinucleotide proportions were used as the response variable and the *IFNL4* SNP rs12979860 genotype as a categorical explanatory variable. We included the first two viral PCs and the first three host PCs as covariates.

### Effect of the three IFN-λ4 protein variants {#s4-4-5}

To estimate the effect of the IFN-λ4 protein variants on the encoded HCV amino acids, we used the 76 sites associated with *IFNL4* SNP rs12979860 at a 10% FDR. HCV-infected patients were classified into three groups according to their predicted ability to produce IFN-λ4 protein: (i) no IFN-λ4 (two allelic copies of IFN-λ4-Null, N~BOSON~ = 145, N~EAP~ = 41), (ii) IFN-λ4--S70 (two copies of IFN-λ4-S70 or one copy of IFN-λ4-S70 and one copy of IFN-λ4-Null, N~BOSON~ = 48, N~EAP~ = 7), and (iii) IFN-λ4-P70 (at least one copy of IFN-λ4-P70, N~BOSON~ = 218, N~EAP~ = 26). We then used logistic regression to estimate the effect sizes (log(OR)) for IFN-λ4-P70 and IFN-λ4-S70 on the virus amino acids relative to IFN-λ4-Null. The presence and absence of the reported viral amino acid was used as the response variable and the host IFN-λ4 status was used as the explanatory variable with the IFN-λ4-Null used as the base level and the log(OR) for IFN-λ4-P70 and IFN-λ4-S70 were estimated relative to the IFN-λ4-Null base level. We included the first two viral PCs and the first three host PCs as covariates to account for host-virus populations co-structuring.

To test whether the effect sizes of IFN-λ4-P70 and IFN-λ4-S70 on viral amino acids are the same, we used the above estimated effect sizes and fitted a linear regression line to it. One viral site (position 2371) was excluded from this analysis as it had unreliable effect size estimate (log(OR) = −17) for IFN-λ4-S70 variant. Under the null hypothesis that IFN-λ4-P70 and IFN-λ4-S70 have the same effect sizes, we would expect that the linear regression line to have a slope of one. To test whether the slope of the fitted line is different from one, we used R to fit a linear regression line with intercept of zero. We used bootstrapping to account for the uncertainty associated with the estimated effect sizes of IFN-λ4-P70 and IFN-λ4-S70 on viral amino acids. We simulated 10,000 bootstrap datasets where the effect sizes of each IFN-λ4 variant on each HCV amino acid were simulated using a normal distribution with mean set to the estimated effect size of the variant on that HCV amino acid and standard deviation set to the standard error of the estimate. For each dataset we fitted a linear regression with intercept of zero and estimated the slope of the fit. The empirical bootstrap 95% confidence interval of the slope of the line was estimated as \[2\* best_estimate_slope -- 97.5%\_quantile_of_bootstrap_slopes, 2\* best_estimate_slope -- 2.5%\_quantile_of_bootstrap_slopes\]. The 'best_estimate_slope' is the slope of the line estimated from the effect sizes without accounting for uncertainty.

To assess whether the mean viral load was different in the three patient groups of IFN-λ4-Null, IFN-λ4-P70 and IFN-λ4-S70, we used a Bayesian framework to perform model comparison (see Appendix 1 for further details). The models we considered comprised fixed and independent effects between the IFN-λ4 variants. We standardised the log10(viral load) so that it had a mean of zero and standard deviation of one. We used linear regression to get maximum likelihood estimates of the effects of IFN-λ4-S70 and IFN-λ4-P70 variants relative to the IFN-λ4-Null variant. The estimates were adjusted for cirrhosis status and population structure including the first two viral PCs and the first three host PCs in the regression as covariates. For each effect size, we assumed a normally distributed prior on the log(OR) of association with mean of zero. The prior covariance matrix determined the prior model assumptions. The elements of the covariance matrix were chosen such that the relevant prior model was set (see Appendix 1 for details).

To assess the evidence for interaction between host IFN-λ4 variants and viral amino acid site 2414, we used the same Bayesian framework detailed above. The patients were grouped into six categories based on the host IFN-λ4 variants and the presence or absence of serine at viral site 2414. We standardised the log10(viral load) so that it had a mean of zero and standard deviation of one. We used linear regression to get maximum likelihood estimates of the effects of 'IFN-λ4-Null + 2414 not serine', 'IFN-λ4-P70 + 2414 not serine', 'IFN-λ4-P70 + 2414 serine', 'IFN-λ4-S70 + 2414 not serine', 'IFN-λ4-S70 + 2414 serine' groups relative to the 'IFN-λ4-Null + 2414 serine' group. The estimates were adjusted for cirrhosis status and population structure including the first two viral PCs and the first three host PCs in the regression as covariates. The prior covariance matrix determined the prior model assumptions. The elements of the covariance matrix were chosen such that the relevant prior model was set (see Appendix 1 for details).

Materials and correspondence {#s4-5}
----------------------------
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###### Host *IFNL4* SNP rs12979860 association with HCV amino acids at a 10% FDR.

We used logistic regression to test for association between host *IFNL4* SNP (CC vs. non-CC) and presence and absence of amino acids. We included the first two viral and the first three host PCs as covariates. Only amino acids that were present in at least 20 samples were tested (977 amino acids in 471 sites). For each associated site, we have reported all amino acid with a count of \>= 20 in reducing frequency order and highlighted the most associated amino acid in bold. The amino acid frequency in CC and nonCC patients, the P-value, log(OR), the standard error and q-value are reported for the most associated amino acid at the site.
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Note that the FDR was calculated independently for each viral GWAS against each host SNP. All the significant associations for each viral GWAS (against each of the 500 frequency matched host SNP) are shown in this table.
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###### Host *IFNL4* SNP rs12979860 association with changes from the most common codon to non-synonymous codons in HCV at a 10% FDR.

We used logistic regression to test for association between host *IFNL4* SNP (CC vs. non-CC) and codon changes. We included the first two viral and the first three host PCs as covariates. Only codons at which there were at least 20 synonymous and 20 non-synonymous codons for the most common codon at the site (348 codon sites across the HCV coding sequence) were included in the analysis.
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We used logistic regression to test for association between host *IFNL4* SNP (CC vs. non-CC) and codon changes. We included the first two viral and the first three host PCs as covariate. Only codons at which there were at least 20 synonymous and 20 non-synonymous codons for the most common codon at the site (348 codon sites across the HCV coding sequence) were included in the analysis.
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Human genotype data underlying this manuscript are deposited in the European Genome-phenome Archive under accession code EGAS00001002324. HCV sequence data underlying this manuscript are deposited in GenBank under accession codes KY620313-KY620880. Information on access to the study data is available at <http://www.stop-hcv.ox.ac.uk/data-access>.
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Viral principal components association with host *IFNL4* SNP rs12979860 {#s8}
=======================================================================

The first two viral PCs were clustered with clades on the virus phylogeny ([Figure 1---figure supplement 2a](#fig1s2){ref-type="fig"}). The other PCs changed more gradually and were grouped to a lesser degree with specific clades on the tree. To explore any specific role for *IFNL4* SNP rs12979860 on viral diversity, we tested whether any viral PCs were associated with SNP rs12979860 genotypes in a univariate analysis and observed that the fifth and seventh PCs were associated with *IFNL4* SNP rs12979860 genotypes ([Figure 1---figure supplement 2b--d](#fig1s2){ref-type="fig"}) respectively explaining 0.7% and 0.5% of the total variance in the nucleotide sequences ([Figure 1---figure supplement 1b](#fig1s1){ref-type="fig"}).

To investigate whether the observed associations between *IFNL4* SNP rs12979860 genotypes and viral PCs were due to host-virus population co-structuring, we selected 500 SNPs across the human genome with frequencies similar to the *IFNL4* SNP rs12979860 SNP and tested for association between these SNPs and the viral PCs ([Figure 1---figure supplement 2b](#fig1s2){ref-type="fig"}). If host-virus populations co-structuring was responsible for the observed association between viral PCs and host *IFNL4* SNP rs12979860 genotypes, we would expect these 500 SNPs to also correlate with fifth and seventh viral PCs. At a 10% FDR, none of the viral PCs were associated with any of the 500 frequency-matched SNPs. Overall, these results indicate that the observed association between *IFNL4* SNP rs12979860 genotypes and the two viral PCs is a consequence of biological interaction between the *IFNL4* locus and the virus sequences and not due to population structure or other systematic bias.

Amino acids associated with *IFNL4* SNP rs12979860 genotypes within the viral protein E2 {#s9}
========================================================================================

Twenty-six of the 76 sites (34%) associated with the *IFNL4* locus at 10% FDR lie within the E2 glycoprotein that is involved in virus entry and directly interacts with two critical cell surface receptors, CD81 and SR-BI. Almost half of these IFN-λ4-associated residues are present in the solved E2 core structure. Interestingly, each of these amino acids is located on the surface of E2 ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}) ([@bib31]). Residues 438, 442, 521, 524 and 546 lie on the neutralizing face of E2; four are in regions targeted by neutralizing antibodies known as Epitope II (aa436-446) and Epitope III (aa523-549), which contain CD81-receptor binding residues. Five residues 576, 576d, 577, 578 and 580 are located within the intergenotypic variable region (igVR) that has a role in virion assembly ([@bib2]; [@bib32]). Recent evidence suggests that the igVR is under strong selective pressure during infection and that it may function to modulate exposure of both the CD81 binding region and antibody epitopes on the surface ([@bib3]). This is supported by a study where mutation of igVR residues to alanine reduced binding of non-neutralizing antibodies ([@bib36]). For sites that are not present in the structure, eight lie within hypervariable region 1 (HVR1) (aa384-411), an immunodominant region of E2, and two are in hypervariable region 2 (HVR2) (aa474-482). Residue 399 in the HVR1 has been implicated in receptor interaction with SR-BI and heparan sulphate ([@bib15]; [@bib12]). Remarkably, residues 457, 500, 501, 558 and 662 have all been shown to modulate the presentation of antibody epitopes as mutation to alanine altered antibody binding ([@bib36]). Residue 741 lies within the transmembrane domain (718-742).

While it is well-documented that type I IFNs can impact the B-cell response via direct and indirect mechanisms, there is little information regarding any influence by type III IFNs. Crucially, it has been shown that both naïve and memory B cells express the IFN-λ1 receptor ([@bib17]). Furthermore, there is evidence that type III interferon can influence antibody production ([@bib17]; [@bib21]). Together, our analysis suggests that *IFNL4* may exert selection pressure on E2 modulating the structure such that presentation of receptor binding sites and antibody epitopes are altered.

Viral dinucleotide frequencies in BOSON and EAP cohorts and their association with *IFNL4* SNP rs12979860. {#s10}
==========================================================================================================

To investigate how *IFNL4* impacts on viral sequences, we estimated the dinucleotide frequencies for each HCV sequence in the different *IFNL4* SNP rs12979860 groups (CC vs. non-CC, [Figure 1---figure supplements 7](#fig1s7){ref-type="fig"} and [8](#fig1s8){ref-type="fig"}) in the two cohorts. In the BOSON cohort, the UpA dinucleotide frequency (estimated as the ratio of the observed to expected frequency) was significantly lower in the *IFNL4* non-CC group compared to the CC group (p=2.7×10^−6^) using linear regression adjusting for two viral PCs and three host PCs. On the contrary, the UpG dinucleotide frequency was significantly higher in the *IFNL4* non-CC group compared to the CC group (p=2.3×10^−5^). The CpC and CpA dinucleotide frequencies were also significantly different between the *IFNL4* genotypes (CC vs. non-CC) using a Bonferroni correction for multiple testing (p\<0.003). In the EAP cohort, the same trend, although not significant, was observed for the UpA and UpG dinucleotide frequencies.

Bayesian model comparison for genetic effect sizes on viral load {#s11}
================================================================

We used approximate Bayes factors (ABFs) to estimate the posterior probability of each model of genetic association as described in [@bib11]. The ABF differs from the Bayes Factor in that it depends on a normal approximation of the regression likelihood (up to a constant) as suggested by [@bib51]. For each model of association we assume a prior on the effect size which is normally distributed around zero. By changing the prior covariance (or correlation) of effect sizes we can formally compare models. The ABF for each model is calculated as the ratio of the approximate marginal likelihood of that model to that of the null model where all the prior weight is on an effect size of zero; note that the ABF for the null model is then equal to 1. Under the assumption that exactly one of the models is correct and all models are equally likely a priori, the posterior probability of a given model is calculated as the ABF for that model divided by the sum of the ABFs for all models under consideration.

Calculation of the marginal likelihood requires specification of a prior distribution for the effects as well as maximum likelihood (ML) point estimates of these effects with their asymptotic standard errors. As a concrete example, let us use the IFN-λ4 variants effects on viral load. Using a linear regression we estimate the two effect sizes for IFN-λ4-P70 and IFN-λ4-S70 relative to the IFN-λ4-Null variant and their asymptomatic standard error. These estimates are adjusted for cirrhosis status and population structure by including the fist two viral PCs and the first three host PCs. We then define the covariance prior matrix which in this case is a 2 × 2 matrix indicating the correlation and variances of effect sizes of IFN-λ4-S70 and IFN-λ4-P70 relative to the IFN-λ4-Null variant. The five tested models and their priors are as follows:

1) Both IFN-λ4-S70 and IFN-λ4-P70 have effect sizes of zero (their effects on viral load are identical to the IFN-λ4-Null variant).$$\Sigma_{1} = \begin{bmatrix}
0 & 0 \\
0 & 0 \\
\end{bmatrix}$$

2) IFN-λ4-S70 has an independent effect and IFN-λ4-P70 has an effect size of zero (the effect on viral load is the same as the IFN-λ4-Null variant).$$\Sigma_{2} = \begin{bmatrix}
1 & 0 \\
0 & 0 \\
\end{bmatrix}$$

3) IFN-λ4-S70 has an effect size of zero (the effect on viral load is the same as the IFN-λ4-Null variant) and IFN-λ4-P70 has an independent effect size.$$\Sigma_{3} = \begin{bmatrix}
0 & 0 \\
0 & 1 \\
\end{bmatrix}$$

4) Both IFN-λ4-S70 and IFN-λ4-P70 have independent effect sizes (their effect on viral load are different from the IFN-λ4-Null variant and different from each other).$$\Sigma_{4} = \begin{bmatrix}
1 & 0 \\
0 & 1 \\
\end{bmatrix}$$

5) Both IFN-λ4-S70 and IFN-λ4-P70 have independent and identical effect sizes (their effects on viral load are the same but different from the IFN-λ4-Null variant).$$\Sigma_{5} = \begin{bmatrix}
1 & 1 \\
1 & 1 \\
\end{bmatrix}$$

The approximate marginal likelihood for any given choice of the prior model is then the value of the multivariate normal density at the ML estimate:$$MVN\left( {\begin{bmatrix}
{\hat{\beta}}_{1} \\
{\hat{\beta}}_{2} \\
\end{bmatrix};\begin{bmatrix}
0 \\
0 \\
\end{bmatrix},\ \begin{bmatrix}
{SE_{\beta_{1}}^{2}} & 0 \\
0 & {SE_{\beta_{2}}^{2}} \\
\end{bmatrix} + \ \Sigma_{i}} \right)$$

To investigate the interaction between *IFNL4* genotypes (CC vs. non-CC), viral load and site 2414 in the NS5A viral protein, we used the Bayesian approach detailed above. We divided the patients into six groups (the three variants of IFN-λ4 and presence or absence of serine at viral site 2414). We then fitted a linear regression with standardised log10(viral load) as the response variable and a categorical variable with the six levels as the explanatory variable. Five effect sizes and their standard error were estimated for the groups 'IFN-λ4-Null + 2414 not serine', 'IFN-λ4-P70 + 2414 not serine', 'IFN-λ4-P70 + 2414 serine', 'IFN-λ4-S70 + 2414 not serine', 'IFN-λ4-S70 + 2414 serine' relative to the 'IFN-λ4-Null + 2414 serine' group. We then used the prior covariance matrix (a 5 × 5 matrix) to define 58 models of association (from all effect sizes being zero to all being different). The posterior probability for each model was estimated as described above. Model five, where only the 'IFN-λ4-P70 + 2414 serine' group had an effect size different from the other groups was the most supported (posterior probability = 0.33). Twelve other models had posterior probabilities greater than their prior probabilities. In all these models, the 'IFN-λ4-P70 + 2414 serine' group had an effect size different from the base group. The marginal posterior probability of all the models in which the effect size of group 'IFN-λ4-P70 + 2414 serine' is different from the 'IFN-λ4-P70 + 2414 not serine' is 0.98. Furthermore the marginal posterior probability of all the models in which the effect size of the 'IFN-λ4-P70 + 2414 serine' is different from the 'IFN-λ4-S70 + 2414 serine' is 0.97.

10.7554/eLife.42463.026
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Broad Impact of Interferon Lambda 4 on Hepatitis C Virus Diversity\" for consideration by *eLife*. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Wenhui Li as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Previously, Ansari et al. reported results of a genome-to-genome study of 542 individuals who were chronically infected with HCV (predominantly viral genotype (VGT) 3, but also VGT 2; Ansari et al., 2017). Genotype for the *IFNL4* rs12979860 SNP marker associated with 11 amino acid polymorphisms on the HCV polyprotein (60, 109 \[C\]; 500, 501, 576d, 578, 741 \[E2\]; 2414 \[NS5A\]; 2570, 2576, 2991 \[NS5B\]) based on a 5% false discovery rate (FDR). The strongest association was for 2570 in NS5B; residue 2414 in NS5A associated with HCV RNA levels amongst patients infected with VGT 3a. The present paper, which is restricted to the 485 subjects who were infected with VGT 3a, contains important new data, but the analytical approach used to arrive at these conclusions is complicated and often confusing. A more focused and unified presentation of the results is needed.

Essential revisions:

Ansari et al. have now imputed genotype for *IFNL4* rs368234815, which controls generation of the IFN-λ4 protein, and *IFNL4* rs117648444, a non-synonymous polymorphism that defines a structural variant of the IFN-λ4 protein. Haplotypes comprised of these variants generate different versions of the IFN-λ4 protein. The authors report that variation in the HCV genome and HCV RNA levels associate with these different haplotypes, consistent with previous associations between these functional *IFNL4* haplotypes and HCV clearance. This finding is novel and potentially important, as it would provide additional support that the IFN activity of *IFNL4* affects the observed phenotype.

This finding raises some additional questions:

Re: the effect of the *IFNL4* loci on viral load, does that translate directly to a lower level of viral replication in patients with *IFNL4* P70? Might this be investigated from the diversity of the viral quasi-species found in the patient?

Re: the coupling between *IFNL4* P70 and S2414 in the HCV genome, is *IFNL4* P70 driving selection of a specific amino acid at this position?

In the Nature Genetics paper, *IFNL4* rs12979860 associated with 11 amino acid polymorphisms, but now, in a smaller cohort, that SNP apparently associates with 42 sites (both based on a 5% FDR). The authors should explain the reason for that striking difference and comment more generally about how findings from the current paper differ from the previous publication. Similarly, the paper should be clearer on which data and results are original to this paper with previously published data referenced to the Nature Genetics paper.

The value of including the Expanded Access Programme (EAP) subjects is unclear. EAP contributes only \~15% of the total subjects and differs from the BOSON group regarding important demographic and clinical characteristics (sex, prevalence of cirrhosis, HCV RNA levels), as well as genotype frequencies of rs12979860. If EAP subjects are retained in the revised paper, these differences should be considered in the analysis and addressed in the Discussion.

The reviewers have many questions and concerns about the statistical methods and the analyses.

Multiple testing: FDRs of either 5% or 20%, as well as Bonferroni correction are employed. Unless there are compelling reasons for these different approaches (which should be stated), a uniform approach to multiple testing adjustment should be used. The Abstract states rs12979860 genotype associated with 4% of viral amino acid sites across the HCV polyprotein. Based on the discussion (that finding does not appear in the results), this result is based on a 20% FDR, whereas findings presented in the Results (and the previous paper) are based on a 5% FDR. A 20% FDR seems very high and needs to be justified.

Genomic inflation factor for *IFNL4* rs12979860 and 500 SNPs with similar frequencies: The genome inflation factor (represented by λ) is used to examine assumptions re: cryptic relatedness when a large set of SNP markers are tested for association with a dichotomous trait in a GWAS ([https://www.ncbi.nlm.nih.gov/pubmed/11315092 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019416](https://www.ncbi.nlm.nih.gov/pubmed/11315092%20https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019416)), but it is unclear what is being analyzed here -- association of viral variants with a trait (yes or no host SNP)? Are the assumptions about the distribution of viral variants the same as for distribution of host germline variants, for which this approach was developed? This is not a standard approach to test for unaccounted population structure or other biases and the logic for doing this is unclear. Can the authors provide a reference to support use of this method?

A λ value of 2.16 is extremely high and indicates cryptic relatedness, but in this case that statistic is impossible to interpret it because the approach is not described adequately.

Principal component analysis: What is used for PCA in the host? There is no explanation and the plot differs from those used for GWAS, where study samples are plotted in relation to reference populations.

Which viral PCs were included? Were the PCs used as continuous variables in any models? (Note: \"principal\" is spelled as \"principle\" in several places.)

Assessment of Confounding, Interaction and Mediation: Assessment as to whether adjustment for potential confounders (e.g. sex, age, study \[EAP or BOSON\], cirrhosis) is needed. Were genotypes associated with any patient characteristics? E.g. age or cirrhosis status?

Stratified analyses should be performed to identify possible interactions for those variables, especially sex (interaction between *IFNL4* genotype and sex has been reported for associations with hepatic fibrosis).

The association of *IFNL4* genotype with the frequency of HCV polymorphisms could reflect an effect of *IFNL4* on viral replication rates. To assess that possibility, the investigators should compare the results of two logistic regression models: one that does and one that does not include HCV RNA as an additional covariate to *IFNL4*. Otherwise these paired models should include identical adjustments.

Other comments re: statistical analyses

Subsection "*IFNL4* SNP has a widespread impact on the viral amino acids" first paragraph: how was the \"expected median\" computed?

Subsection "*IFNL4* SNP has a widespread impact on the viral amino acids" second paragraph: was does \"frequency matched\" mean? With the same MAF?

Subsection "Subsection "*IFNL4* SNP has a widespread impact on the viral amino acids" first paragraph", third paragraph: please state outcome variable for the logistic regression models.

Subsection "*IFNL4* SNP has a widespread impact on the viral amino acids", third paragraph: please define FDR and give reference.

Subsection "Statistical analysis", third paragraph: please state clearly that the SNP was the outcome for the logistic models.

Subsection "Statistical analysis", eleventh paragraph: To obtain maximum likelihood estimates one needs to assume a normal distribution for log~10~(viral load) transformed data. IN my experience this assumption is not true for log~10~(viral load) transformed data. However, least squares estimates do not require this assumption.

Subsection "Statistical analysis", eleventh paragraph: when a line was fit through the log(OR) estimates, how were the standard deviations of the log(ORs) used? That uncertainty needs to be accommodated.

Other general comments:

The presentation is hard to follow with most data presented as minimally annotated supplementary materials with limited legends provided separately. Providing more detailed legends next to corresponding figures and tables should make it easier to follow.

In the Discussion, the limitations of the study should be explored.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Interferon lambda 4 impacts on the genetic diversity of hepatitis C virus\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Wendy Garrett as the Senior Editor and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

Overall, the authors were responsive to reviewer comments and the paper is much improved. The analytical approach remains complicated and the paper is still challenging to read. The authors should consider and address the following comments.

Multiple testing: The authors eliminated use of the Bonferroni correction and a false discovery rate (FDR) of 20%. The paper still presents two different FDR thresholds (5% and 10%) for many analyses and the reason for doing so is unclear. It would be simpler to report a single set of results based on a 5% FDR, the threshold used in the previous publication from this group.

Normality of viral load data: It is not clear from a visual inspection of the Q-Q plot that these data are normally distributed. A P-value for fit would be a more objective measure.

Second paragraph of the Introduction "substitutes a proline for a serine \[...\]": Terczyńska-Dyla et. al state, "an amino-acid substitution in the IFNλ4 protein changing a proline at position 70 to a serine (P70S) \[...\]". To this reader, that means a serine is substituted for a proline. Alternatively, the authors might use the language of Terczyńska-Dyla et. al to describe this variant.

Subsection "Host and virus genetic structures": Without any explanation, it is unclear how to interpret the Bayes factors of 249 and 1.1.

How the patients are divided into *IFNL4*-null, S70 and P70 groupings could be clearer. Supplementary file 7 would present that information if the groups were arranged together and labeled.

Subsection "Host and virus genetic structures", ninth paragraph -- The co-submission by Chaturvedi et al. has been accepted for publication and might be referenced here.

10.7554/eLife.42463.027

Author response

> Essential revisions:
>
> Ansari et al. have now imputed genotype for IFNL4 rs368234815, which controls generation of the IFN-λ4 protein, and IFNL4 rs117648444, a non-synonymous polymorphism that defines a structural variant of the IFN-λ4 protein. Haplotypes comprised of these variants generate different versions of the IFN-λ4 protein. The authors report that variation in the HCV genome and HCV RNA levels associate with these different haplotypes, consistent with previous associations between these functional IFNL4 haplotypes and HCV clearance. This finding is novel and potentially important, as it would provide additional support that the IFN activity of IFNL4 affects the observed phenotype.
>
> This finding raises some additional questions:
>
> Re: the effect of the IFNL4 loci on viral load, does that translate directly to a lower level of viral replication in patients with IFNL4 P70? Might this be investigated from the diversity of the viral quasi-species found in the patient?

We note the comment from the reviewers on whether the viral load translates directly to a lower level of viral replication. While lower viral replication (i.e. replication of viral RNA) could contribute to reduced viral load, we would not exclude a contribution from other parts of the viral life cycle, especially since the *IFNL4* footprint extends across both structural and non-structural proteins. Studies on the effects on viral RNA replication would require further analysis. However, during the review process, we are aware of a new report from Thomas Baumert's group which reveals interplay between the innate immune response (IFITM proteins) and neutralization antibodies (Wrensch et al., Hepatology in press) that affect virus entry. Moreover, their study shows there is a change in the amino acids encoded by E2 from acute to chronic infection that generates IFITM-resistance. One of the sites that changes is at position 500 in the E2 protein, which is a position associated with *IFNL4* genotype in our study (see Figure 1---figure supplement 2). Thus there could be differences in the interferon response dependent on *IFNL4* genotype (i.e. producers vs. non-producers) that affects stages of the virus life cycle other than RNA replication (e.g. virus entry as in the Wrensch et al. paper or also translation, assembly and release). All of the above is addressed in the Discussion. As to the second point raised by the reviewer about whether lower viral load may influence the diversity of quasispecies, our analysis has not investigated the viral quasispecies in individuals (i.e. intra-host viral diversity); all of our analysis has been conducted on the consensus sequences and in this way, we have examined inter-host viral diversity. We agree with the reviewer that any reduction in viral load mediated by *IFNL4*-P70 could influence the quasispecies at the intra-host level. However, this would require a deeper analysis of the sequence data, preferably combined with functional in vitro studies.

> Re: the coupling between IFNL4 P70 and S2414 in the HCV genome, is IFNL4 P70 driving selection of a specific amino acid at this position?

Since there is a significant association between serine at position 2414 and *IFNL4*-P70 variant, our interpretation would be that *IFNL4*-P70 does exert selection of S2414. However, this is potentially true also for the other associated sites that have statistical significance. This point is made in the revised Abstract (see final sentence). However, specifically in relation to S2414, we have added the following sentence to the paper: "The viral serine (S) residue at site 2414 (S2414) was significantly enriched in *IFNL4*-P70 carrying patients compared to *IFNL4*-S70 (P = 3.39x10^-03^) and *IFNL4*-Null (P = 5.94x10^-09^) carrying patients. S2414 was present in 86% (211/244) of IFNL-P70 carrying patients, 69% (38/55) of *IFNL4*-S70 carrying patients and 62% (114/185) of *IFNL4*-Null carrying patients."

> In the Nature Genetics paper, IFNL4 rs12979860 associated with 11 amino acid polymorphisms, but now, in a smaller cohort, that SNP apparently associates with 42 sites (both based on a 5% FDR). The authors should explain the reason for that striking difference and comment more generally about how findings from the current paper differ from the previous publication. Similarly, the paper should be clearer on which data and results are original to this paper with previously published data referenced to the Nature Genetics paper.

Our previous analysis in the Nature Genetics paper used 542 samples from individuals with different ethnic backgrounds (the two main ethnic groups were white \[n=452\] and Asian \[n=74\]). Additionally these individuals were infected by HCV genotypes 2 (n=45) and 3 (n=496) with different subtypes (gt3a, gt3b and gt3c). That study was aimed mainly at identifying any human genes that may be associated with viral polymorphisms. Not surprisingly, we identified viral variants that were linked to HLA alleles. Surprisingly, we found that *IFNL4* genotype was also associated with variants in the virus polyprotein. However, the depth of the study was limited by the mixture of ethnicities and viral genotypes/subtypes in the BOSON cohort. We believe that our current report does not simply confirm the findings in the Nature Genetics paper but expands and enhances the extent of the footprint of *IFNL4* genotype on variants in the viral polyprotein.

With regard to the increased number of associated sites, there are two major factors compared to our previous report that contribute to this enhancement. Firstly, in the current paper, we have limited the dataset to individuals with self-reported white ancestry infected with HCV gt3a to avoid potential bias due to co-structuring between host and virus populations. To increase the power of the study, we included 74 patients from another cohort, the EAP cohort, who were also of white ethnicity and infected with gt3a. This gave a total of 485 patients with identical ethnic background and infection with the same HCV genotype/subtype. As with any GWAS study, confidence in statistically significant associations is greater with more data and this was a major factor for inclusion of the EAP group. The EAP and BOSON cohorts do differ with regard to severity of liver disease; the EAP cohort consists largely of patients with decompensated cirrhosis while the BOSON cohort were recruited on the basis of milder disease. We did not find that differences in disease severity affected our analysis (see below). Therefore, the associations between *IFNL4* genotype and viral variants in gt3a apparently apply irrespective of the extent of liver disease.

The second important difference between the two studies is that in the Nature Genetics paper we used a different methodology to analyse the impact of SNP rs12979860 on the viral variants. In the Nature Genetics paper, we used phylogenetically corrected Fisher's exact test to measure associations and account for population structure. For this method we inferred the phylogenetic tree of the viral sequence data, estimated ancestral viral sequences and compared them to the viral sequences at the tips of the tree. The presence and absence of changes was then tested for association with SNP rs12979860. However, in the current study we apply logistic regression and account for population structure by including viral and host genetic PCs as covariates in the analysis. This approach has recently been shown to be more powerful to detect association in genome-to-genome analysis (Correcting for Population Stratification Reduces False Positive and False Negative Results in Joint Analyses of Host and Pathogen Genomes; DOI=10.3389/fgene.2018.00266). Thus, focusing on a homogenous population (white ethnicity infected with gt3a) and using logistic regression has increased the power of our study to detect many more associations between the SNP rs12979860 and the HCV amino acids.

We have now expanded the second paragraph in the Discussion to compare the findings in this study with those in the Nature Genetics paper.

> The value of including the Expanded Access Programme (EAP) subjects is unclear. EAP contributes only \~15% of the total subjects and differs from the BOSON group regarding important demographic and clinical characteristics (sex, prevalence of cirrhosis, HCV RNA levels), as well as genotype frequencies of rs12979860. If EAP subjects are retained in the revised paper, these differences should be considered in the analysis and addressed in the Discussion.

Although the EAP group represents a lesser proportion of the cohort, our aim has been to gather as many well-characterised samples in terms of viral sequence and clinical data as possible. As stated above, increasing the scale of the group under study enhances the confidence in any statistical analysis for identifying associations. Moreover, the viral sequence data was generated by similar methods in Oxford and Glasgow using target enrichment probe sets and next generation sequencing. The viral sequence data generated does not use HCV-specific primers and so the sequences produced are not biased. Putting together such a large number of sequences covering almost the entire length of the viral genome is not a trivial task. Additionally, we tested and found no association between the HCV phylogenetic tree (which estimates the population structure of the virus) and the host INFL4 SNP rs12979860 (using treeBreaker as indicated in the subsection "Host and virus genetic structures" and Figure 1---figure supplement 3B). Furthermore, we also performed all of the analysis in the BOSON cohort alone and found similar association results that are reported in the Materials and methods. Finally, we have performed an analysis testing for association between the cohort of origin of the patient and viral amino acid variants and found no significant associations (see below). Therefore, we believe that there are sound reasons for combining the BOSON and EAP cohorts.

> The reviewers have many questions and concerns about the statistical methods and the analyses.
>
> Multiple testing: FDRs of either 5% or 20%, as well as Bonferroni correction are employed. Unless there are compelling reasons for these different approaches (which should be stated), a uniform approach to multiple testing adjustment should be used. The Abstract states rs12979860 genotype associated with 4% of viral amino acid sites across the HCV polyprotein. Based on the discussion (that finding does not appear in the results), this result is based on a 20% FDR, whereas findings presented in the Results (and the previous paper) are based on a 5% FDR. A 20% FDR seems very high and needs to be justified.

Firstly, we have modified the Abstract to remove the statement on association with 4% of viral amino acid sites across the viral polyprotein. In addition, we have modified the text to use 5% and 10% FDR thresholds throughout the manuscript.

> Genomic inflation factor for IFNL4 rs12979860 and 500 SNPs with similar frequencies: The genome inflation factor (represented by λ) is used to examine assumptions re: cryptic relatedness when a large set of SNP markers are tested for association with a dichotomous trait in a GWAS ([https://www.ncbi.nlm.nih.gov/pubmed/11315092 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019416](https://www.ncbi.nlm.nih.gov/pubmed/11315092%20https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0019416)), but it is unclear what is being analyzed here -- association of viral variants with a trait (yes or no host SNP)? Are the assumptions about the distribution of viral variants the same as for distribution of host germline variants, for which this approach was developed? This is not a standard approach to test for unaccounted population structure or other biases and the logic for doing this is unclear. Can the authors provide a reference to support use of this method?
>
> A λ value of 2.16 is extremely high and indicates cryptic relatedness, but in this case that statistic is impossible to interpret it because the approach is not described adequately.

We have modified the text to simplify this section. We have tested presence and absence of each viral variant (amino acid or codon) against host SNPs (the rs12979860 SNP was converted to binary variables to indicate CC vs. non-CC genotypes and the other 500 SNPs with similar frequencies were similarly converted to binary variables to indicate homozygous for major allele vs. other genotypes). In other words we have performed 501 viral GWASs and in each GWAS the trait of interest is a host SNP (SNP rs12979860 and 500 other SNPs with similar frequencies).

In this revised version of the manuscript, we decided to present the results differently and to remove the genomic inflation factor. We have observed 42 association signals with *IFNL4* SNP rs12979860 at a 5% FDR, whilst 491 of the 500 SNPs with a similar allele frequency showed no association signal and 9 showed only one association signal. If host-virus population co-structuring was contributing to our results, we would expect to observe similar patterns between HCV amino acid variants and the other host SNPs frequency-matched to *IFNL4* SNP. Similarly, only the *IFNL4* SNP rs12979860 showed a distribution of observed P-values different from the distribution of P-values for a null hypothesis of no associations, as shown on the qqplots. We moved the qqplot figure to a figure supplement and added a Manhattan plot of the associations (Figure 1).

To answer the reviewer's question, we detail as follows our assumptions for the genomic inflation factor as presented in the earlier version. For each of the viral GWASs against the 500 frequency-matched host SNPs, we calculated a genomic inflation factor. Only the viral GWAS with SNP rs12979860 as the outcome variable had inflated P-values, while none of viral GWASs with any other host SNP (outside of the IFNLs loci) as the outcome variable had inflated P-values. If co-structuring of host and virus populations or cryptic relatedness or other systematic biases were driving the inflation in the P-values of viral GWAS against host rs12979860 SNP, we would expect to observe the same effect for other host SNPs. As Figure 1---figure supplement 6A show, our viral GWAS P-values against all other host SNPs follow the expected null hypothesis of no association.

> Principal component analysis: What is used for PCA in the host? There is no explanation and the plot differs from those used for GWAS, where study samples are plotted in relation to reference populations.

We used FlashPCA to perform PCA on the host genotype data. We performed this analysis only in the studied cohorts (all with self-reported white ethnicity) and did not include reference populations. This was to ensure that we were capturing lower level population structures in our cohort that may otherwise be lost in the context of global population structure. It is a standard analysis to do in human genetics with a homogenous cohort, even if it might not be the most reported one in the literature.

> Which viral PCs were included? Were the PCs used as continuous variables in any models?

Viral sequence data were converted into binary variables which was then used for PCA. We used the first two PCs (as continuous variables) in all our viral GWASs unless indicated otherwise in the text.

> (Note: \"principal\" is spelled as \"principle\" in several places.)

We modified the text accordingly.

> Assessment of Confounding, Interaction and Mediation: Assessment as to whether adjustment for potential confounders (e.g. sex, age, study \[EAP or BOSON\], cirrhosis) is needed. Were genotypes associated with any patient characteristics? E.g. age or cirrhosis status?
>
> Stratified analyses should be performed to identify possible interactions for those variables, especially sex (interaction between IFNL4 genotype and sex has been reported for associations with hepatic fibrosis).

We assessed the impact of the above potential confounders on the viral amino acid variation. We performed four separate viral GWASs using logistic regression (one for each possible confounder). Presence and absence of viral amino acids was used as the response variable and 2 viral PCs, 3 host PCs and *IFNL4* SNP rs12979860 (CC vs. non-CC genotype) were added as covariates. FDR was calculated for each viral GWAS independent of the others. At 10% FDR there were no significant associations between cirrhosis status, cohorts (BOSON vs. EAP), gender and age, and any of the viral amino acid variants.

We included the following sentence to the Results section: "To test for possible confounders we added separately the cirrhosis status, cohorts (BOSON vs. EAP), gender and age to the model as covariates. These covariates were not associated with any specific amino acids at 10% FDR (data not shown)."

In a separate viral GWAS, we investigated whether the interaction between *IFNL4* SNP rs12979860 genotypes and gender had an impact on viral amino acid variation. We used the same procedure as above, adding 2 viral PCs, 3 host PCs, *IFNL4* SNP rs12979860 (CC vs. non-CC genotype) and gender as covariates. At 10% FDR there was no significant association between any viral amino acids and the interaction term of *IFNL4* SNP rs12979860 and gender.

We also performed another analysis where we compared the impact of *IFNL4* SNP rs12979860 (CC vs. non-CC genotypes) on viral amino acid variation, using two different logistic regression models. In model one, we used 2 viral PCs and 3 host PCs as covariates and in the second model we also added age, gender, cirrhosis status and cohort indicator as covariates. The P-values for the association between *IFNL4* SNP rs12979860 and the viral amino acid variants are highly correlated between the two models as shown in [Author response image 1](#respfig1){ref-type="fig"}.

Since the results were negative, we decided not to include the two former interaction analyses in the revised paper to keep it as simple as possible.

![](elife-42463-resp-fig1){#respfig1}

> The association of IFNL4 genotype with the frequency of HCV polymorphisms could reflect an effect of IFNL4 on viral replication rates. To assess that possibility, the investigators should compare the results of two logistic regression models: one that does and one that does not include HCV RNA as an additional covariate to IFNL4. Otherwise these paired models should include identical adjustments.

We agree that *IFNL4* SNP rs12979860 is associated with viral load such that CC patients on average have higher viral load and this could indicate the impact of *IFNL4* on viral replication rates. Higher levels of replication in CC patients could lead to more within-patient diversity, but we have shown that non-synonymous codon changes are much more likely to be associated with *IFNL4* SNP rs12979860 compared to synonymous codon changes. Additionally, unless there is a form of selection acting on specific amino acids, one cannot explain consistent changes to the same amino acid across multiple patients with the same *IFNL4* genotype.

However, we performed the above comparison suggested by the reviewer. In the first model we included 2 viral PCs and 3 host PCs as covariates and in the second model we also added log10(viral load) as a covariate to the model. We plotted the P-values of associations between *IFNL4* SNP rs12979860 and the viral amino acids from the two models against each other. Adding log10(viral load) as a covariate reduced the P-values very slightly as shown in [Author response image 2](#respfig2){ref-type="fig"}, but the impact on the analysis was minimal. At a 5% FDR 37 viral sites were associated with host INFL4 SNP, increasing to 68 at 10% FDR.

![](elife-42463-resp-fig2){#respfig2}

> Other comments re: statistical analyses
>
> Subsection "IFNL4 SNP has a widespread impact on the viral amino acids" first paragraph: how was the \"expected median\" computed?

To estimate the genomic inflation factor we calculated the median of the observed chi-squared test statistics and divided it by the median of the chi-squared distribution with one degree of freedom which is 0.4549 (expected median). The P-values were converted to chi-squared test statistics using qchiseq(1-p, df=1) in R. However we removed this section from the current version to simplify the presentation of the Results as indicated above.

> Subsection "IFNL4 SNP has a widespread impact on the viral amino acids" second paragraph: was does \"frequency matched\" mean? With the same MAF?

We modified the text as follows: we performed the same tests against HCV amino acids for 500 host SNPs from across the human genome with a minor allele frequency (MAF) similar to *IFNL4* SNP rs12979860 MAF, further referred to as the "500 frequency-matched SNPs":

> Subsection "IFNL4 SNP has a widespread impact on the viral amino acids" first paragraph", third paragraph: please state outcome variable for the logistic regression models.

We have modified the text to indicate that the presence and absence of viral amino acids was used as the outcome variable in the logistic regression models.

> Subsection "IFNL4 SNP has a widespread impact on the viral amino acids", third paragraph: please define FDR and give reference.

We have modified the text as follows: at 5% false discovery rate (FDR) which indicates the expected number of false positives among discoveries (significant associations). We added a reference (Benjamini and Hochberg, 1995).

> Subsection "Statistical analysis", third paragraph: please state clearly that the SNP was the outcome for the logistic models.

In the last paragraph of the subsection "Human and viral population structure", we did not use logistic regression. We used treeBreaker software (Ansari and Didelot, 2016). This software uses Bayesian methodology to measure association between a tree and a phenotype of interest. In brief, given a tree and tip phenotypes, it infers which clades on the tree, if any, have a distinct distribution of the tip phenotype from the rest of the tree.

> Subsection "Statistical analysis", eleventh paragraph: To obtain maximum likelihood estimates one needs to assume a normal distribution for log~10~(viral load) transformed data. IN my experience this assumption is not true for log~10~(viral load) transformed data. However, least squares estimates do not require this assumption.

The qqplot of the model residuals against standard normal distribution indicates that the assumption of normality is justified.
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> Subsection "Statistical analysis", eleventh paragraph: when a line was fit through the log(OR) estimates, how were the standard deviations of the log(ORs) used? That uncertainty needs to be accommodated.

We have modified our analysis to account for the uncertainty associated with the log(ORs). To do this we used bootstrapping. We simulated 10,000 bootstrap datasets where the log(ORs) were simulated using a normal distribution with mean set to the log(ORs) and standard deviation set to the standard error of the estimate. For each dataset we fitted a linear regression and estimated the slope of the fit. The empirical bootstrap 95% confidence interval of the slope of the line was in (0.69,0.99) which does not include 1.

> Other general comments:
>
> The presentation is hard to follow with most data presented as minimally annotated supplementary materials with limited legends provided separately. Providing more detailed legends next to corresponding figures and tables should make it easier to follow.

The *eLife* submission process requires us to submit supplementary figures and legends separately. We hope that in the final version of this manuscript, legends will be provided next to the corresponding figure or table.

> In the Discussion, the limitations of the study should be explored.

We have included a paragraph (second last) in the Discussion on the limitations of the study.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> Overall, the authors were responsive to reviewer comments and the paper is much improved. The analytical approach remains complicated and the paper is still challenging to read. The authors should consider and address the following comments.
>
> Multiple testing: The authors eliminated use of the Bonferroni correction and a false discovery rate (FDR) of 20%. The paper still presents two different FDR thresholds (5% and 10%) for many analyses and the reason for doing so is unclear. It would be simpler to report a single set of results based on a 5% FDR, the threshold used in the previous publication from this group.

False discovery rate allows us to quantify the expected number of false positives in our results. Choosing a low FDR will ensure that there are very few false positives, but setting a low FDR value also risks reducing the number of true positives. In the present version of the manuscript, we decided to report both 5% and 10% FDR thresholds. The reason for doing so is that a large number of associated viral amino acids were required for analyses to be performed with sufficient power. This could only be achieved with a 10% FDR. In our previous publication, we also used two different FDR thresholds (5% and 20%). The lower 5% FDR is applied in this present work to help with comparisons to our previous report.

> Normality of viral load data: It is not clear from a visual inspection of the Q-Q plot that these data are normally distributed. A P-value for fit would be a more objective measure.

This comment is related to the first set of reviews that we received. "Subsection "Statistical analysis", eleventh paragraph: To obtain maximum likelihood estimates one needs to assume a normal distribution for log~10~(viral load) transformed data. IN my experience this assumption is not true for log~10~(viral load) transformed data. However, least squares estimates do not require this assumption."

We answered this comment in the rebuttal by presenting a qq-plot. No modification was added to the manuscript. Here, we explain the reason why we are confident that the tests performed in the manuscript are valid.

In small samples most statistical methods do require distributional assumptions, and the case for distribution-free rank-based tests is relatively strong. However, in large data sets (which is the case for our study), most statistical methods rely on the Central Limit Theorem, which states that the average of a large number of independent random variables is approximately normally distributed around the true population mean. It is this normal distribution of an average that underlies the validity of the t-test and linear regression, but also of logistic regression and of most software for the Wilcoxon and other rank tests.

The t-test and linear regression compare the mean of an outcome variable for different subjects. While these are valid even in very small samples if the outcome variable is normally distributed, their major usefulness comes from the fact that in large samples they are valid for any distribution (Lumley et al. The importance of the normality assumption in large public health data sets. Annu Rev Public Health. 2002;23:151-69).

> Second paragraph of the Introduction "substitutes a proline for a serine \[...\]": Terczyńska-Dyla et. al state, "an amino-acid substitution in the IFNλ4 protein changing a proline at position 70 to a serine (P70S) \[...\]". To this reader, that means a serine is substituted for a proline. Alternatively, the authors might use the language of Terczyńska-Dyla et. al to describe this variant.

We modified the text to read "the IFN-λ4 protein, which changes a proline residue at position 70 (P70) to a serine residue (S70)". We are not using the P70S nomenclature elsewhere in the article so would prefer not to introduce it here. We hope the change will make the description of the variant clearer and accurate.

> Subsection "Host and virus genetic structures": Without any explanation, it is unclear how to interpret the Bayes factors of 249 and 1.1.

We added the following sentences: "see Materials and methodsfor an explanation on how to interpret Bayes factor' and in the Materials and methods section: 'Bayes factor is a summary of the evidence provided by the data in favour of one model compared to another. \[...\] Bayes factor: 10 to 100, strong evidence against null model and in favour of the alternative model. Bayes factor: \>100, decisive evidence against null model and in favour of the alternative model."

> How the patients are divided into IFNL4-null, S70 and P70 groupings could be clearer. Supplementary file 7 would present that information if the groups were arranged together and labeled.

We modified the Supplementary file 7 to include a row labeling the different haplotypes into the grouping that we made. Each haplotype is now linked to the protein predicted to be produced.

We also added the following sentence in the Materials and methods section: "HCV-infected patients were classified into three groups according to their predicted ability to produce IFN-λ4 protein: (i) no IFN-λ4 (two allelic copies of IFN-λ4-Null, N~BOSON~=145, N~EAP~=41), (ii) IFN-λ4--S70 (two copies of IFN-λ4-S70 or one copy of IFN-λ4-S70 and one copy of IFN-λ4-Null, N~BOSON~=48, N~EAP~=7), and (iii) IFN-λ4-P70 (at least one copy of IFN-λ4-P70, N~BOSON~=218, N~EAP~=26)."

> Subsection "Host and virus genetic structures", ninth paragraph -- The co-submission by Chaturvedi et al. has been accepted for publication and might be referenced here.

We added the following sentence: (also see 'Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes' by Chaturvedi *et al.* in this issue).

[^1]: These authors also contributed equally to this work.

[^2]: These authors also contributed equally to this work.
